Compare Stocks

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVO Evotec	$7.25 -0.5%	$7.42	$6.83 ▼ $13.49	$2.57B	1.36	74,455 shs	36,469 shs
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	$30.83 -0.4%	$31.07	$27.54 ▼ $31.90	$912.57M	0.79	133,160 shs	75,304 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVO Evotec	-0.55%	-7.88%	+5.22%	-12.97%	+724,999,900.00%
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	-0.36%	-2.62%	-1.19%	+5.37%	+2.73%

Elon Musk’s ChatGPT Could Soon Mint New Millionaires (Ad)

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVO Evotec	1.5001 of 5 stars	3.5	3.0	0.0	0.0	1.9	0.0	0.6
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVO Evotec	3.00	Buy	$14.00	93.10% Upside
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	0.00	N/A	$39.83	29.18% Upside

Current Analyst Ratings

Latest LTG, GEM, TRB, 3PL, and EVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/12/2024	EVO Evotec	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
1/18/2024	EVO Evotec	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVO Evotec	$791.73M	3.25	N/A	N/A	$3.53 per share	2.05
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVO Evotec	-$185.07M	N/A	0.00	51.79	N/A	N/A	N/A	N/A	N/A
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	N/A	N/A	10.49	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVO Evotec	N/A	N/A	N/A	N/A	N/A
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	$0.84	2.72%	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVO Evotec	N/A	2.16	2.09
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
EVO Evotec	5.81%
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	N/A

Insider Ownership

Company	Insider Ownership
EVO Evotec	N/A
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EVO Evotec	4,952	354.37 million	N/A	Not Optionable
GEM Goldman Sachs ActiveBeta Emerging Markets Equity ETF	N/A	29.60 million	N/A	Not Optionable

LTG, GEM, TRB, 3PL, and EVO Headlines

Source	Headline
	Goldman Sachs Access Emerging Markets USD Bond ETF declares monthly distribution of $0.1794 msn.com - April 2 at 12:17 PM
	Goldman Sachs sees surge in hedge fund interest in crypto msn.com - March 25 at 12:04 AM
	Goldman bumps up 2023 pay for top three executives by 24% msn.com - March 15 at 1:20 PM
	Goldman Sachs Investment Expert Warns Against Investing In China: 'It Is Not Clear What The Overall General Direction Of Policy Will Be Long Term' msn.com - March 5 at 9:59 AM
	Goldman Sachs Has 3 New Staple Stock Favorites msn.com - March 4 at 2:40 AM
	Goldman Sachs, Mubadala Strike $1 Billion Deal for Private Credit Investment in Asia Pacific msn.com - February 26 at 7:23 AM
	Goldman Sachs Secures $1B Private Credit Deal With Abu Dhabi's Mubadala To Capitalize On Surging Interest In Asia-Pacific Market benzinga.com - February 26 at 2:21 AM
	Goldman Lifts S&P 500 Target To 5,200 On Profit Expansion bloomberg.com - February 20 at 9:33 PM
	Goldman Sachs faces probe over fees charged for futures trading- Bloomberg News reuters.com - February 8 at 1:49 PM
	Goldman Sachs management committee is getting an overhaul: Wall Street Journal msn.com - February 2 at 5:54 PM
	Goldman Sachs co-head of global banking and markets departs thetradenews.com - January 30 at 7:38 AM
	Goldman Sachs digital assets chief explains bank's participation in bitcoin ETF boom msn.com - January 23 at 8:19 PM
	Breaking Down Goldman Sachs' Q4 Triumph: What Investors Need To Know seekingalpha.com - January 16 at 1:43 PM
	Goldman Sachs earnings top forecasts as stock trading offsets deal slump msn.com - January 16 at 8:43 AM
	Goldman Sachs almost doubles profits, but reports drop in net earnings for 2023 financial results invezz.com - January 16 at 8:43 AM
	Goldman Sachs offers 10 reasons why it’s more confident about the U.S. economy msn.com - January 15 at 7:41 AM
	Goldman Sees 6% Equity Growth In 2024 fa-mag.com - January 11 at 5:35 PM
	Etsy and Revolve Group fall after Goldman Sachs warns on consumer spending trends msn.com - January 10 at 10:40 AM
	Goldman Sachs role in BlackRock ETF makes approval more likely invezz.com - January 7 at 8:15 AM
	Goldman Sachs ActiveBeta Emerging Markets Equity ETF declares quarterly distribution of $0.1739 msn.com - December 27 at 1:35 PM
	Goldman's painful lesson on China forces rethink of emerging markets msn.com - December 26 at 11:50 PM
	Goldman Sachs Access Emerging Markets USD Bond ETF declares monthly distribution of $0.1937 msn.com - December 6 at 8:48 AM
	Goldman Sachs 2024 stock strategy - sales growth msn.com - November 20 at 7:20 AM
	Goldman Sachs Maintains Sell Rating for Williams-Sonoma: Here's What You Need To Know markets.businessinsider.com - November 17 at 12:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
3 Large-Cap Stocks Buying Back Shares Aggressively
March 18, 2024 6:15 AM
View 3 Large-Cap Stocks Buying Back Shares Aggressively
You Can Follow BlackRock’s Market View for Your Money
April 12, 2024 10:00 AM
View You Can Follow BlackRock’s Market View for Your Money

All Headlines

Company Descriptions

Evotec

NASDAQ:EVO

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Goldman Sachs ActiveBeta Emerging Markets Equity ETF

NYSEARCA:GEM

The Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) is an exchange-traded fund that mostly invests in total market equity. The fund tracks an index of emerging market stocks comprising 4 sub-indexes: value, momentum, quality, and low volatility. The index uses multiple factors to pick stocks, and each sub-index receives equal weight. GEM was launched on Sep 29, 2015 and is managed by Goldman Sachs.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial